[1]
Yamashita, Y., Hori, Y., Kosako, H., Oiwa, T., Warigaya, K., Mushino, T., Murata, S., Fujimoto, M., Nishikawa, A., Murata, S.- ichi, Sonoki, T. and Tamura, S. 2020. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em&gt; overexpression. Hematology Reports. 12, 1 (May 2020). DOI:https://doi.org/10.4081/hr.2020.8368.